PPD has been building relationships with Polish investigators since 1995 with the opening of its Warsaw office. Having a reliable investigator network gives clients access to eager, untreated patients, which in turn expedites clinical trial timelines.
Poland, the region’s largest pharmaceutical market, is well-regarded for its quality of medical training and compliance with good clinical practice (GCP) principles. Short regulatory approval timelines and improved intellectual property protections are helping accelerate drug development.
Learn about the benefits and challenges of conducting clinical trials in Central and Eastern Europe. Download our white paper.